- Home
- CHRS
as 05-16-2025 4:00pm EST
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.
| Founded: | 2010 | Country: | United States |
| Employees: | N/A | City: | REDWOOD CITY |
| Market Cap: | 112.5M | IPO Year: | 2014 |
| Target Price: | $5.26 | AVG Volume (30 days): | 1.7M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.14 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.66 - $2.43 | Next Earning Date: | 05-12-2025 |
| Revenue: | $272,251,000 | Revenue Growth: | 19.87% |
| Revenue Growth (this year): | -62.1% | Revenue Growth (next year): | -2.17% |
Latest Coherus BioSciences Inc. News
CHRS Breaking Stock News: Dive into CHRS Ticker-Specific Updates for Smart Investing
Simply Wall St.
6 days ago
Coherus BioSciences First Quarter 2025 Earnings: Misses Expectations
Thomson Reuters StreetEvents
7 days ago
Q1 2025 Coherus BioSciences Inc Earnings Call
GuruFocus.com
7 days ago
Coherus BioSciences Inc (CHRS) Q1 2025 Earnings Call Highlights: Strategic Growth and ...
Zacks
7 days ago
Coherus BioSciences (CHRS) Reports Q1 Loss, Lags Revenue Estimates
Associated Press Finance
7 days ago
Coherus BioSciences: Q1 Earnings Snapshot
GlobeNewswire
7 days ago
Coherus BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update
GuruFocus.com
11 days ago
What To Expect From Coherus BioSciences Inc (CHRS) Q1 2025 Earnings
GlobeNewswire
14 days ago
Coherus to Report First Quarter 2025 Financial Results on May 12, 2025
Compare CHRS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CHRS Coherus BioSciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.